Skip to main content Accessibility help
Hostname: page-component-59b7f5684b-9m8n8 Total loading time: 1.548 Render date: 2022-09-29T05:16:53.240Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "displayNetworkTab": true, "displayNetworkMapGraph": false, "useSa": true } hasContentIssue true

Nuts and CVD

Published online by Cambridge University Press:  07 July 2015

Emilio Ros*
Lipid Clinic, Endocrinology and Nutrition Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Barcelona, Spain CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
*Corresponding author: E. Ros, fax +34 93 4537829, email
Rights & Permissions[Opens in a new window]


Nuts are nutrient-dense foods with complex matrices rich in unsaturated fatty acids and other bioactive compounds, such as l-arginine, fibre, healthful minerals, vitamin E, phytosterols and polyphenols. By virtue of their unique composition, nuts are likely to beneficially affect cardiovascular health. Epidemiological studies have associated nut consumption with a reduced incidence of CHD in both sexes and of diabetes in women, but not in men. Feeding trials have clearly demonstrated that consumption of all kinds of nuts has a cholesterol-lowering effect, even in the context of healthy diets. There is increasing evidence that nut consumption has a beneficial effect on oxidative stress, inflammation and vascular reactivity. Blood pressure, visceral adiposity and the metabolic syndrome also appear to be positively influenced by nut consumption. Contrary to expectations, epidemiological studies and clinical trials suggest that regular nut consumption is not associated with undue weight gain. Recently, the PREvención con DIeta MEDiterránea randomised clinical trial of long-term nutrition intervention in subjects at high cardiovascular risk provided first-class evidence that regular nut consumption is associated with a 50 % reduction in incident diabetes and, more importantly, a 30 % reduction in CVD. Of note, incident stroke was reduced by nearly 50 % in participants allocated to a Mediterranean diet enriched with a daily serving of mixed nuts (15 g walnuts, 7·5 g almonds and 7·5 g hazelnuts). Thus, it is clear that frequent nut consumption has a beneficial effect on CVD risk that is likely to be mediated by salutary effects on intermediate risk factors.

Full Papers
Copyright © The Author 2015 

By definition, tree nuts are dry fruits with one seed in which the ovary wall becomes hard at maturity. Common edible tree nuts include almonds, Brazil nuts, cashews, hazelnuts, macadamia nuts, pecans, pine nuts, pistachios and walnuts, but the consumer definition also includes peanuts, which are botanically legumes but have a nutrient profile similar to that of tree nuts and are thus identified as part of the nuts food group(Reference Sabaté, Salas-Salvadó and Ros1). For the purpose of this review, the term ‘nuts’ comprises all common tree nuts (with the exception of chestnuts, which are starchy and contain little fat compared with other tree nuts) plus peanuts.

Extensive research on nuts and health outcomes has been conducted since the publication in the early 1990s of the results of two landmark studies: the Adventist Health Study, which related frequent nut consumption to a lower risk of CHD(Reference Fraser, Sabaté and Beeson2) and the randomised clinical trial (RCT) of Sabaté et al. (Reference Sabaté, Fraser and Burke3) showing that walnut intake reduced serum cholesterol levels, as had also been shown for almonds(Reference Spiller, Jenkins and Cragen4).

Together with cereal grains and legumes, nuts have been regular constituents of human diet since pre-agricultural times(Reference Eaton and Konner5). Whole grains, legumes and nuts are high-energy, nutrient-dense seeds. In the outer layer and the germ, all seeds are made of complex matrices, rich in minerals, vitamins and bioactive phytochemicals that serve the purpose of protecting the plant's DNA from oxidative stress, thus facilitating the perpetuation of the species, while the endosperm stores a complete mixture of macronutrients destined to sustain the future seedling. Most seed components are bioavailable after consumption by humans and many of them synergise in the body to beneficially affect metabolic and vascular physiology pathways leading to protection from CVD and diabetes(Reference Ros and Hu6).

The scientific evidence behind the proposal of seeds in general and nuts in particular as heart-healthy foods stems from both epidemiological observations and RCT. As recently reviewed(Reference Kris-Etherton, Hu and Ros7, Reference Ros, Tapsell and Sabaté8), large observational studies have shown that the frequency of nut consumption relates inversely to incident CHD and diabetes, while numerous short-term feeding trials comparing nut-enriched diets with control diets have demonstrated beneficial effects on blood lipids and other intermediate markers of cardiovascular risk. The accruing evidence on the beneficial cardiovascular effects of nuts has prompted the inclusion of this food group in many guidelines for healthful eating. Thus, in the summer of 2003, the US Food and Drug Administration issued a health claim for nuts and nut-containing products because of the link of nut consumption with a reduced risk of heart disease(9). Also, nuts were included in the American Heart Association report setting goals for health promotion and disease reduction for 2020(Reference Lloyd-Jones, Hong and Labarthe10) and in both the recent Canadian Cardiovascular Society Guidelines(Reference Anderson, Grégoire and Hegele11) and the newest American Heart Association/American College of Cardiology guideline on lifestyle management to reduce cardiovascular risk(Reference Eckel, Jakicic and Ard12); furthermore, nuts are integral part of plant-based dietary patterns recommended to the general population for health(13) and are an important component and part of the definition of the Mediterranean diet(Reference Bach-Faig, Berry and Lairon14). Here, we summarise present knowledge on the expanding topic of nut consumption and CVD.

Nutrient content of nuts

Nutrient-dense nuts are one of the natural plant foods rich in fat after vegetable oils, with a total fat content ranging from 46 % in cashews and pistachios to 76 % in macadamia nuts (Table 1). The fatty acid composition of nuts is beneficial because the SFA content is low (range 4–16 %) and nearly one-half of the total fat content is made up of unsaturated fat, mostly MUFA, although sizeable proportions of PUFA, predominantly linoleic acid, are present in Brazil nuts, pine nuts and walnuts(Reference Ros and Mataix15). Of note, walnuts are also a rich source of α-linolenic acid, the plant n-3 fatty acid(Reference Ros and Mataix15). As discussed below, the particular lipid profile of nuts in general and walnuts in particular is likely to be an important contributor to the beneficial health effects of frequent nut consumption.

Table 1 Average composition of nuts in macro- and micronutrients and selected phytochemicals (per 100 g)*

LA, linoleic acid; ALA, α-linolenic acid; PS, plant sterols; NR, not reported.

* Sources: US Department of Agriculture Nutrient Data Base. (accessed 24 March 2014); National Institute for Health and Welfare, N.U. Fineli. Finnish Food Composition Database. (accessed 24 March 2014); and Phenol-Explorer 3.0. Data base on polyphenol content in foods. (accessed 24 March 2014).

Nuts are also rich sources of other bioactive macronutrients with potential health benefits(Reference Sabaté, Salas-Salvadó and Ros1). Thus, nuts are a good source of protein (approximately 25 % of energy) and often have a high content of the amino acid l-arginine, which is the substrate for endothelium-derived NO synthesis, a main regulator of vascular tone and blood pressure(Reference Moncada and Higgs16). This might explain the positive effects of nut intake on vascular reactivity, as discussed below. Nuts are also a good source of dietary fibre, which ranges from 4 to 11 g/100 g(Reference Salas-Salvadó, Bulló and Pérez-Heras17) (Table 1). Among nut constituents, there are significant amounts of essential micronutrients that are associated with an improved health status when consumed at doses beyond those necessary to prevent deficiency states. They include sizeable amounts of the B vitamin folate and antioxidant vitamins (e.g. tocopherols) and polyphenols(Reference Vinson and Cai18). It is important to know that most of the antioxidants in nuts are located in the pellicle or outer soft shell, as shown for almonds(Reference Milbury, Chen and Dolnikowski19), which means that significant quantities are lost when nuts are peeled or roasted. These facts should be considered when giving advice on nut consumption in healthful diets. Walnuts are an exception because they are usually consumed as the raw, unpeeled product; moreover, walnuts have the highest polyphenol content of all nuts(Reference Vinson and Cai18).

Nuts are free of cholesterol, but their fatty fraction contains sizeable amounts of phytosterols(Reference Segura, Javierre and Lizarraga20), which are likely to contribute to their cholesterol-lowering effect (see below). Also, nuts have an optimal nutritional density regarding beneficial minerals such as Ca, Mg and K(Reference Ros and Hu6, Reference Segura, Javierre and Lizarraga20). As in the case of most vegetables, the Na content of nuts is very low (Table 1). A high intake of Ca, Mg and K, together with a low Na intake, is associated with protection against hypertension, insulin resistance and overall cardiovascular risk(Reference Karppanen, Karppanen and Mervaala21), besides bone demineralisation.

In summary, the macronutrient, micronutrient and phytochemical components of nuts have been documented to contribute to a reduced risk of CHD and related metabolic disturbances. This might explain why nut consumption is associated with reduced cardiovascular risk in both observational studies and RCT, as discussed below.

Nut consumption and cardiovascular health

Nut consumption has been the subject of much epidemiological and clinical research. Prospective studies have examined clinical cardiovascular end points, i.e. CHD, stroke, type 2 diabetes, hypertension and the metabolic syndrome, while RCT have generally explored intermediate biomarkers of CVD risk(Reference Kris-Etherton, Hu and Ros7, Reference Ros, Tapsell and Sabaté8). An exception is the PREvención con DIeta MEDiterránea (PREDIMED) trial of primary cardiovascular prevention, which included nut supplementation in one study arm and had hard cardiovascular end points as the main outcome(Reference Estruch, Ros and Salas-Salvadó22). The scientific evidence acquired from these studies is summarised below.

Epidemiological studies

Four large prospective studies conducted in the USA examining associations of dietary components with health outcomes reported a beneficial effect of nut consumption on fatal and non-fatal CHD after follow-up ranging from 6 to 18 years(Reference Fraser, Sabaté and Beeson2, Reference Hu, Stampfer and Manson23Reference Blomhoff, Carlsen and Andersen25). These studies were reviewed in 2006 by Kelly & Sabaté(Reference Kelly and Sabaté26), who estimated an 8·3 % reduction in CHD risk for each weekly serving of nuts. Protection against CHD mortality with increasing nut consumption was also observed in the PREDIMED study population when assessing the cohort as a longitudinal study(Reference Guasch-Ferré, Bulló and Martínez-González27). A recent report of two large cohorts of women from the Nurses' Health Study (NHS) and men from the Health Professionals Follow-up Study with follow-up of 30 and 24 years, respectively, again showed reduced CHD mortality for both sexes with increasing nut consumption(Reference Bao, Han and Hu28) (Fig. 1). Remarkably, nut consumption was also associated with a reduction in all-cause and cancer mortality in these two reports(Reference Guasch-Ferré, Bulló and Martínez-González27, Reference Bao, Han and Hu28). An additional report from the NHS concerning women with type 2 diabetes further evaluated the relationship between nut consumption and CVD (including CHD and stroke) and observed a multivariable adjusted 54 % lower risk of CVD(Reference Li, Brennan and Wedick29). Although considering nuts and fruits together, findings from the prospective Greek European Prospective Investigation into Cancer and Nutrition cohort also suggest a protective effect of higher consumption against CHD, with 23 and 34 % risk reductions for men and women, respectively(Reference Dilis, Katsoulis and Lagiou30). A dose–response relationship between nut consumption and reduced CHD mortality was observed in all studies. Consistent findings in all prospective studies strongly suggest a causal association between nut consumption and reduced CHD rates.

Fig. 1 Incidence of fatal CHD by frequency of nut intake. Shown are the results of six large prospective studies where nut consumption was the exposure of interest and the outcome was death from CHD. , Adventist Health Study, 1992; , Nurses' Health Study, 1998; , Physicians' Health Study, 2002; , Iowa Women's Health Study, 2006; , PREvención con DIeta MEDiterránea, 2013; , Nurses' Health Study and Health Professionals Follow-up Study, 2013. A colour version of this figure can be found online at

The findings of prospective studies are less consistent regarding nut consumption and stroke risk. Thus, a non-significant decreased risk of fatal stroke with increasing nut consumption was reported for postmenopausal women participating in the Iowa Women's Health Study(Reference Yochum, Folsom and Kushi31); no association between frequency of nut consumption and stroke risk was observed in men from the Physicians' Health Study(Reference Djoussé, Gaziano and Kase32), and an additional report of the large NHS and Health Professionals Follow-up Study cohorts showed that regular nut consumption related to a weak but significant lower risk of stroke in women, but not in men(Reference Bernstein, Pan and Rexrode33).

The association between nut consumption and type 2 diabetes risk has also been investigated in prospective studies. Findings from the large NHS cohort suggested that nut and peanut butter consumption was associated with a reduced incidence of diabetes in women(Reference Jiang, Manson and Stampfer34). No such relationship was observed in postmenopausal women participating in the Iowa Women's Health Study(Reference Parker, Harnack and Folsom35). A subsequent report from a Chinese cohort of nearly 64 000 women also showed that nut consumption protected from diabetes risk(Reference Villegas, Gao and Yang36). These findings, however, were not confirmed in male participants in the Physicians' Health Study(Reference Kochar, Gaziano and Djoussé37). A more recent report from a large cohort of women combining data from NHS and NHS II after follow-up of 10 years showed that consumption of walnuts, but not other nuts, was associated with reduced rates of incident diabetes(Reference Pan, Sun and Manson38). Finally, a cross-sectional assessment of the PREDIMED cohort of older persons at high cardiovascular risk showed a reduced prevalence of diabetes with increasing nut consumption(Reference Ibarrola-Jurado, Bulló and Guasch-Ferré39). In this study, a lower prevalence of the metabolic syndrome, a high-cardiovascular risk cluster of risk factors related to insulin resistance, was also observed in frequent nut eaters(Reference Ibarrola-Jurado, Bulló and Guasch-Ferré39). Similarly, nut consumption is related to lower incident metabolic syndrome in the prospective Seguimiento Universidad de Navarra cohort of Spanish university graduates(Reference Fernández-Montero, Bes-Rastrollo and Beunza40) and in a large cross-sectional report from the US National Health and Nutrition Examination Survey for 2001–4(Reference O'Neil, Keast and Nicklas41).

Four prospective studies have evaluated the frequency of nut consumption in relation to incident hypertension(Reference Steffen, Kroenke and Yu42Reference Weng, Steffen and Szklo45). In the young biracial cohort of the Coronary Artery Risk Development in Young Adults study, subjects in the upper category of nut consumption had a 15 % decreased risk of hypertension compared with the lowest category after 15 years of follow-up(Reference Steffen, Kroenke and Yu42). In the large Physicians' Health Study men cohort(Reference Djoussé, Rudich and Gaziano43), the risk of hypertension was reduced by 18 % in participants who consumed nuts daily compared with non-consumers, although the benefit was restricted to participants who were not overweight or obese at baseline. Another report from the Seguimiento Universidad de Navarra cohort found a non-significant 23 % lower risk of incident hypertension for the highest v. lowest nut consumption category after 4·3 years of follow-up(Reference Martínez-Lapiscina, Pimenta and Beunza44). Moreover, a recent report from the Atherosclerosis Risk in Communities study in middle-aged adults showed a 13 % lower risk of incident hypertension in the top quintile of nut consumption compared with the bottom quintile after follow-up for 9 years(Reference Weng, Steffen and Szklo45). The US National Health and Nutrition Examination Survey 2001–4 cross-sectional study also reported lower prevalent hypertension for nut consumers compared with non-consumers(Reference O'Neil, Keast and Nicklas41).

As reviewed(Reference Kris-Etherton, Hu and Ros7, Reference Ros, Tapsell and Sabaté8), prospective studies have also reported an association between increasing nut consumption and reduced circulating levels of inflammatory biomarkers.

In summary, the results of several prospective studies strongly suggest that regular consumption of nuts is beneficial for CHD risk. The risk of stroke in relation to nut consumption has been less investigated compared with CHD risk, and data support a weak protective effect in women, but not in men. Confirmation of a protective role on stroke as well as diabetes risk must await further studies. Data from epidemiological studies also suggest a protective effect of nut consumption on the metabolic syndrome and hypertension, one of its components. Finally, there is also suggestive epidemiological evidence that frequent nut consumption is associated with reduced systemic inflammation.

Randomised clinical trials with outcomes on intermediate biomarkers

RCT to investigate the effects on cardiovascular risk factors and an attempt to understand the underlying mechanisms for protection from CHD followed the first observational studies. Most RCT have compared diets supplemented with nuts with control diets for outcomes on blood lipid changes in individuals with normal or moderately elevated blood cholesterol levels. Some studies have also evaluated the effects of nuts on glycaemic control in patients with type 2 diabetes. Other studies have focused on the relevant question of whether unrestricted nut intake influences body weight. Further RCT have assessed the effects of nut diets on intermediate risk markers, such as blood pressure, insulin sensitivity, endothelial function and inflammatory status. Almonds and walnuts have been the most studied nuts, followed by pistachios. The long-term PREDIMED trial has targeted both the effects of nut consumption on intermediate cardiometabolic markers and clinical outcomes, such as the metabolic syndrome, diabetes and cardiovascular events, among others. Given the relevance of PREDIMED for the issue of nuts and cardiovascular health, its results will be dealt within a separate section.

Since the first RCT by Sabaté et al. (Reference Sabaté, Fraser and Burke3) examining the lipid effects of nuts showed that a walnut diet reduced blood cholesterol levels in healthy individuals, the effects of nut consumption on blood lipids and lipoproteins have been investigated in many studies. A pooled analysis of twenty-five RCT conducted in seven countries examining nut-enriched diets v. control diets during periods of 3–8 weeks for outcomes on blood lipids clearly demonstrated that nuts had a cholesterol-lowering effect that was related to both dose and baseline cholesterol level, stratified by sex and across all age groups, and independent of the type of nut tested(Reference Sabaté, Oda and Ros46). Specifically, daily consumption of 67 g (2·4 oz) of nuts was associated with mean reduction of 10·9 mg/dl (5·1 %) in total cholesterol, 10·2 mg/dl (7·4 %) in LDL-cholesterol and 0·22 (8·3 %) in LDL:HDL ratios (P< 0·001, all). Nuts had no significant effect on HDL-cholesterol or TAG, except in participants with serum TAG >150 mg/dl, in whom a significant mean 10·2 mg/dl reduction was observed. A separate meta-analysis of thirteen RCT examined the effect of walnut-enriched diets on blood lipid levels(Reference Banel and Hu47). Compared with control diets, diets enriched with walnuts in amounts ranging from 30 to 108 g/d (10–24 % of energy) were associated with weighed mean reductions of total cholesterol and LDL-cholesterol of 10·3 and 9·2 mg/dl (P< 0·001, both), respectively, which are similar to those described in the pooled analysis for different nut types(Reference Sabaté, Oda and Ros46). RCT testing the lipid effects of nuts have usually been short term, but efficacy is maintained in the long term. Thus, inclusion of walnuts (12 % of energy) to the usual diet of free-living individuals to whom no dietary advice was given during a 6-month period reduced total cholesterol by 5 mg/dl (P= 0·02) and TAG by 8 mg/dl (P= 0·03), with a nearly significant decrease of 3·5 mg/dl in LDL cholesterol (P= 0·06)(Reference Torabian, Haddad and Cordero-MacIntyre48). Also, a walnut diet against a control diet for up to 1 year in obese patients with type 2 diabetes showed maintained, albeit small, LDL-cholesterol reductions and HDL-cholesterol increases with the walnut diet(Reference Tapsell, Batterham and Teuss49).

Acute studies using test meals with a high glycaemic index with or without nuts have shown reduced postprandial glucose responses with nut meals, suggesting that nuts may be useful in controlling diabetes(Reference Kendall, Josse and Esfahani50). Improved glycaemic control has been recently reported in patients with type 2 diabetes fed diets enriched with 2 oz mixed nuts(Reference Jenkins, Kendall and Banach51) or almonds(Reference Li, Liu and Liu52)v. control diets for 12 weeks. It may seem counterintuitive to recommend energy-dense nuts to diabetic patients for the fear of gaining weight. Indeed, there is a widespread perception that all fatty foods provide excess energy and promote obesity, which has had a negative effect on the image of nuts. However, there is no epidemiological or RCT evidence that their frequent consumption promotes weight gain; on the contrary, reports from large prospective cohorts show inverse associations between the frequency of nut consumption and BMI or weight gain over time after adjustment for confounders(Reference Fraser, Sabaté and Beeson2, Reference Hu, Stampfer and Manson23, Reference Bes-Rastrollo, Sabaté and Gómez-Gracia53Reference Mozaffarian, Hao and Rimm55). Similar findings regarding BMI together with reduced waist circumference have been shown for increasing nut consumption in cross-sectional studies(Reference O'Neil, Keast and Nicklas41, Reference Casas-Agustench, Bulló and Ros56, Reference Martínez-González, García-Arellano and Toledo57) and in the PREDIMED cohort considered as a longitudinal study(Reference Ibarrola-Jurado, Bulló and Guasch-Ferré39). Finally, a recent meta-analysis of RCT that tested nut diets v. control diets showed small non-significant associations of nut intake with reduced adiposity measures(Reference Flores-Mateo, Rojas-Rueda and Basora58), as had been previously described for walnut trials(Reference Banel and Hu47). Mechanistically, the lack of weight gain after consuming nuts is largely due to their prominent satiating effect, which results in food compensation accounting for up to 75 % of the energy they provide(Reference Mattes, Kris-Etherton and Foster59). An additional factor contributing to offset energy acquisition after eating nuts is fat malabsorption, documented as increased faecal fat excretion, which is due in part to incomplete digestion of their matrices because the fat of nuts is enclosed within cell membranes, which are not readily available to digestive enzymes even after thorough mastication(Reference Ellis, Kendall and Ren60). In conclusion, a substantial body of evidence permits to allay fear of undue weight gain when eating these high-fat foods.

The unique composition of nuts in bioactive nutrients and phytochemicals suggests that their consumption can beneficially affect cardiometabolic markers other than blood lipids and glycaemic control. A few studies have examined the effects of nuts on oxidative stress, inflammation and vascular reactivity, as reviewed(Reference Kris-Etherton, Hu and Ros7, Reference Ros, Tapsell and Sabaté8, Reference Ros61, Reference Casas-Agustench, López-Uriarte and Ros62). A growing body of evidence from small RCT indicates that nuts, particularly walnuts, have beneficial effects on endothelial function, as ascertained by flow-mediated dilatation studies in the brachial artery(Reference Ros, Núñez and Pérez-Heras63Reference West, Krick and Klein66), reduced circulating levels of endothelial activation molecules(Reference Zhao, Etherton and Martin67) or inhibition of pro-inflammatory cytokine production by blood mononuclear cells(Reference Zhao, Etherton and Martin68). While an effect of nut diets on resting blood pressure has been difficult to detect in clinical studies, testing haemodynamic responses to stress has uncovered a beneficial effect of walnuts(Reference West, Krick and Klein66) and pistachios(Reference West, Gebauer and Kay69) on blood pressure and total peripheral resistance, suggesting a novel mechanism for the cardioprotective effects of nuts. Improved vascular reactivity in studies with walnuts may be ascribed to their richness in l-arginine, PUFA, particularly α-linolenic acid, and polyphenols(Reference Casas-Agustench, López-Uriarte and Ros62).

Nuts being a rich source of antioxidants, it is not surprising that their consumption has been related to improved oxidative status(Reference López-Uriarte, Bulló and Casas-Agustench70). This has been reported for MUFA-rich nuts, such as almonds, both acutely(Reference Jenkins, Kendall and Marchie71) and after 1 month feeding(Reference Jenkins, Kebdall and Marchie72), pistachios(Reference Kay, Gebauer and West73) and hazelnuts(Reference Orem, Yucesan and Orem74), but not for PUFA-rich nuts such as walnuts, albeit no deleterious effects on oxidation have been described(Reference Banel and Hu47, Reference López-Uriarte, Bulló and Casas-Agustench70). Studies on nut-feeding have documented reduced circulating concentrations of inflammatory cytokines but no consistent changes of C-reactive protein(Reference Banel and Hu47, Reference Ros61). A novel mechanism by which walnut consumption may reduce cardiovascular risk has recently been reported: increased cholesterol efflux from cholesterol-laden macrophages exposed to human serum collected after a walnut meal(Reference Berryman, Grieger and West75). Cholesterol efflux from macrophages is an important step in the anti-atherogenic reverse cholesterol transport pathway. This is a provocative finding that needs to be confirmed in further studies; it suggests that nut (walnut) consumption improves the functionality of HDL, the main lipoprotein particles involved in reverse cholesterol transport. In this sense, another recent report of a PREDIMED substudy showed that the Mediterranean diet enriched with mixed nuts shifted both LDL and HDL subfractions to a less atherogenic pattern, also suggesting improved cholesterol transport capacity after nut diets(Reference Damasceno, Sala-Vila and Cofán76). In summary, the emerging picture is that nut consumption has positive effects on cardiovascular risk factors well beyond established cholesterol lowering without incurring increases in adiposity.

Cardiovascular effects of nuts in the PREvención con DIeta MEDiterránea trial

The PREDIMED study is a large, parallel group, multi-centre, 5-year RCT of nutrition intervention conducted in Spain. Eligible participants were men, 55–80 years of age, and women, 60–80 years of age, at high risk but no CVD at enrolment. Participants were randomised to three diet groups, two Mediterranean diets, supplemented with either extra-virgin olive oil or mixed nuts, or control diet (advice on a low-fat diet). They received quarterly individual and group educational sessions and, depending on group assignment, free provision of extra-virgin olive oil (one litre/week), mixed Mediterranean nuts (30 g/d: 15 g walnuts, 7·5 g almonds and 7·5 g hazelnuts) or small non-food gifts. Of note, the diets were non-energy restricted and increased physical activity was not promoted; thus, the full effect of dietary intervention alone could be ascertained. The primary end point was an aggregate of major cardiovascular events (myocardial infarction, stroke and cardiovascular death).

Since its inception in October 2003, the results of the trial have provided much evidence on the beneficial health effects of Mediterranean diets enriched with both supplemental foods, culminating with the findings concerning the primary end point(Reference Estruch, Ros and Salas-Salvadó22). The efficacy of the PREDIMED nutritional intervention has generally been similar for both the extra-virgin olive oil and nut-supplemented Mediterranean diets in comparison with the control diet. The main results regarding the Mediterranean diet enriched with mixed nuts are summarised below.

In a study involving the first 772 participants completing intervention for 3 months(Reference Estruch, Martínez-González and Corella77), results showed that, compared with the control diet, the two Mediterranean diets resulted in significant reductions of both systolic and diastolic blood pressure and total and LDL-cholesterol; increased HDL-cholesterol; decreased fasting glucose levels in diabetic participants and increased insulin sensitivity in those without diabetes; and reduction in circulating levels of inflammatory cytokines. Both intervention diets were also associated with reduced oxidised LDL levels(Reference Fitó, Guxens and Corella78). The nut-enriched diet reduced fasting TAG levels as well(Reference Estruch, Martínez-González and Corella77). While results on lipids, glycaemic control and oxidation and inflammation biomarkers were confirmatory of previous data, the blood pressure-lowering effect of the nut-enriched diet was novel. Of note, reduced blood pressure by both PREDIMED Mediterranean diets after intervention for 1 year has recently been confirmed in a 24 h ambulatory blood pressure monitoring substudy(Reference Doménech, Roman and Lapetra79).

Another substudy investigated both 3-month changes in circulating inflammatory biomarkers and the expression of ligands for inflammatory molecules in circulating monocytes after the intervention(Reference Mena, Sacanella and Vázquez-Agell80). The findings indicate reductions in both circulating inflammatory mediators and, importantly, reduced monocyte expression of pro-inflammatory ligands after the two Mediterranean diets, thus beginning to unravel the molecular bases for their anti-inflammatory effects. Concurring with these findings, a recent 2-year vascular imaging study in a PREDIMED subcohort detected an anti-atherosclerotic effect of the Mediterranean diets v. the control diet, namely delayed progression of carotid intima-media thickness and plaque, which was more pronounced with the nut-supplemented diet(Reference Sala-Vila, Romero-Mamani and Gilabert81).

The effects of the interventions on the metabolic syndrome status and incident diabetes were secondary end points of the PREDIMED study. In the first 1224 trial participants completing intervention for 1 year, the nut-enriched Mediterranean diet was associated with a 14 % reduction in the prevalence of the metabolic syndrome, which was mainly due to reduced visceral adiposity(Reference Salas-Salvadó, Fernández-Ballart and Ros82). Because there were no weight changes, this suggests fat redistribution away from the abdominal compartment. In one of the eleven PREDIMED recruiting centres, annual oral glucose tolerance tests were performed in non-diabetic participants to accurately detect incident diabetes. Results in 418 subjects followed for a mean of 4 years showed that both Mediterranean diets protected against development of diabetes, and the reduction of incident diabetes in the nuts arm was 52 % compared with the control diet(Reference Salas-Salvadó, Bulló and Babio83). Again, this beneficial effect took place in the absence of weight loss or increased energy expenditure in physical activity. More recently, the results on diabetes incidence for the full PREDIMED cohort have become available and this time the nut-enriched diet only showed a non-significant 18 % reduction(Reference Salas-Salvadó, Bulló and Estruch84).

Recently, the results of the PREDIMED trial on the primary end point have been reported, showing for the first time a reduction of incident CVD after long-term consumption of the two Mediterranean diets(Reference Estruch, Ros and Salas-Salvadó22). After a median follow-up of 4·8 years in 7447 participants, those assigned the two Mediterranean diets showed a 30 % reduction in CVD events (myocardial infarction, stroke or cardiovascular death) compared with the control diet. As seen in Fig. 2, the curves of the two Mediterranean diet groups and the control group diverged soon after the beginning of the study. Such an early (and sustained) reduction in cardiovascular events fits with the improvement of intermediate markers of CVD detected after follow-up for only 3 months(Reference Estruch, Martínez-González and Corella77, Reference Fitó, Guxens and Corella78, Reference Mena, Sacanella and Vázquez-Agell80). The nut diet was also associated with a significant 49 % reduction in stroke risk(Reference Estruch, Ros and Salas-Salvadó22). The two intervention diets were associated with non-significant reductions in myocardial infarction and no effect could be discerned on total mortality, although one must keep in mind that the trial was not powered for these outcomes. Of note, the interventions were intended to improve the overall dietary pattern, but the major between-group differences in food intake were for the supplemental items. Thus, nuts were probably responsible for most of the observed benefit in the corresponding Mediterranean diet group. A protective effect of both intervention diets on peripheral arterial disease, another cardiovascular outcome, has also been reported recently(Reference Ruiz-Canela, Estruch and Corella85).

Fig. 2 Incidence of CVD by intervention group in the PREvención con DIeta MEDiterránea study. Med Diet with extra-virgin olive oil (EVOO): hazard ratios (HR) 0·70 (95 % CI 0·53, 0·91), P= 0·009; Med Diet with nuts: HR 0·70 (95 % CI 0·53, 0·94), P= 0·016. Med Diet, Mediterranean diet. Estruch et al. (Reference Estruch, Ros and Salas-Salvadó22) copyright© (2013) Massachusetts Medical Society. Reprinted with permission. A colour version of this figure can be found online at

The beneficial effects shown in various PREDIMED reports for the Mediterranean diet with nuts on intermediate biomarkers of cardiovascular risk include blood pressure, the lipid profile, insulin resistance, lipoprotein oxidation and systemic inflammation. This diet was also associated with reduction in visceral adiposity, metabolic syndrome and diabetes, as well as delayed atherosclerosis progression. Taken together, these multivariate effects provide a mechanistic explanation for the observed protection of the nut-supplemented diet against CVD. The results of the PREDIMED trial show the full potential of nuts and other healthy foods such as extra-virgin olive oil to improve cardiovascular health.


Nuts are high-energy, nutrient-dense seeds rich in beneficial macronutrients, micronutrients and bioactive phytochemicals. The unique composition of nuts appears to be of paramount importance for their health effects. There is truly consistent evidence from epidemiological and clinical studies of the salutary effects in the consumption of individual nut components and whole nuts on the risk for CVD, as well as on diabetes and major and emerging cardiovascular risk factors, as summarised in Table 2. An increasing body of scientific evidence indicates that including nuts in a healthy dietary pattern affords protection against cardiometabolic disorders beyond that attributable to the other components of a healthy diet. Importantly, contrary to popular belief due to the high energy content of nuts, their consumption does not induce undue weight gain, or is even associated with reduced adiposity, which is attributable in part to satiation and subsequent lesser intake of alternate high-energy foods. Nut components such as unsaturated fatty acids, l-arginine, beneficial minerals, phenolic compounds and phytosterols target multiple cardiovascular risk factors and metabolic pathways, which explain why nuts so strongly reduce cardiovascular risk. The PREDIMED trial has provided first-level evidence that long-term adherence to a healthful diet enriched with one daily serving of mixed nuts reduces the incidence of type 2 diabetes and CVD, particularly stroke. Ongoing research in the context of this landmark trial will eventually indicate whether the salutary effects of nuts extend to prevention of other prevalent chronic diseases, including cancer and neurodegenerative disorders.

Table 2 Effects of nut consumption on CVD and risk factors. Summary of scientific evidence

++, evidence from several studies; +, limited evidence from few studies; +/ − , equivocal evidence; PREDIMED, PREvención con DIeta MEDiterránea.

* Evidence collected in the PREDIMED trial, among others.

Oxidation improved with nuts rich in MUFA (i.e. almonds, pistachios and hazelnuts) and unchanged with nuts rich in PUFA (i.e. walnuts).

Evidence collected only in the PREDIMED trial.


The present study was supported in part by grants from the Instituto de Salud Carlos III (ISCIII), the Spanish Ministry of Economy and Competitiveness (CIBERobn) and the California Walnut Commission (CWC), Sacramento, CA. Neither ISCIII nor CWC had any role in the design, analysis or writing of this article. CIBERobn is an initiative of the ISCIII, Spain.

The author has received funds for research through his institution from the CWC and is a non-paid member of its Scientific Advisory Committee.


1Sabaté, J, Salas-Salvadó, J & Ros, E (editors) (2006) Nuts: nutrition and health outcomes. Br J Nutr 96, Suppl. 2, S1102.CrossRefGoogle ScholarPubMed
2Fraser, GE, Sabaté, J, Beeson, WL, et al. (1992) A possible protective effect of nut consumption on risk of coronary heart disease. The Adventist Health Study. Arch Intern Med 152, 14161424.CrossRefGoogle ScholarPubMed
3Sabaté, J, Fraser, GE, Burke, K, et al. (1993) Effects of walnuts on serum lipid levels and blood pressure in normal men. N Engl J Med 328, 603607.CrossRefGoogle ScholarPubMed
4Spiller, GA, Jenkins, DJ, Cragen, LN, et al. (1992) Effect of a diet high in monounsaturated fat from almonds on plasma cholesterol and lipoproteins. J Am Coll Nutr 11, 126130.Google ScholarPubMed
5Eaton, SB & Konner, M (1985) Paleolithic nutrition. A consideration of its nature and current implications. N Engl J Med 312, 283289.CrossRefGoogle ScholarPubMed
6Ros, E & Hu, FB (2013) Consumption of plant seeds and cardiovascular health: epidemiological and clinical trial evidence. Circulation 128, 553565.CrossRefGoogle ScholarPubMed
7Kris-Etherton, PM, Hu, FB, Ros, E, et al. (2008) The role of tree nuts and peanuts in the prevention of coronary heart disease: multiple potential mechanisms. J Nutr 138, 1746S1751S.CrossRefGoogle ScholarPubMed
8Ros, E, Tapsell, LC & Sabaté, J (2010) Nuts and berries for heart health. Curr Atheroscler Rep 12, 397406.CrossRefGoogle ScholarPubMed
9US Food and Drug Administration (2003) Qualified Health Claims: Letter of Enforcement Discretion – Nuts and Coronary Heart Disease. Rockville, MD: US Food and Drug Administration, pp. 14.Google Scholar
10Lloyd-Jones, DM, Hong, Y, Labarthe, D, et al., American Heart Association Strategic Planning Task Force and Statistics Committee (2010) Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation 121, 586613.CrossRefGoogle ScholarPubMed
11Anderson, TJ, Grégoire, J, Hegele, RA, et al. (2013) 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 29, 151167.CrossRefGoogle ScholarPubMed
12Eckel, RH, Jakicic, JM, Ard, JD, et al. (2014) 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63, Pt B, 29602984. Erratum in (2014) J Am Coll Cardiol 63, Pt B, 3027–3028.CrossRefGoogle Scholar
13U.S. Department of Health and Human Services and U.S. Department of Agriculture (2010) Dietary Guidelines for Americans, 2010, 7th ed.Washington, DC: U.S. Government Printing Office.Google Scholar
14Bach-Faig, A, Berry, EM, Lairon, D, et al. (2011) Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr 14, 22742284.CrossRefGoogle ScholarPubMed
15Ros, E & Mataix, J (2006) Fatty acid composition of nuts. Implications for cardiovascular health. Br J Nutr 96, Suppl. 2, S29S35.CrossRefGoogle ScholarPubMed
16Moncada, S & Higgs, A (1993) The l-arginine–nitric oxide pathway. N Engl J Med 329, 20022012.Google ScholarPubMed
17Salas-Salvadó, J, Bulló, M, Pérez-Heras, A, et al. (2006) Dietary fibre, nuts and cardiovascular diseases. Br J Nutr 96, Suppl. 2, S45S51. Erratum in (2008) Br J Nutr 99, 447–448.CrossRefGoogle ScholarPubMed
18Vinson, JA & Cai, Y (2012) Nuts, especially walnuts, have both antioxidant quantity and efficacy and exhibit significant potential health benefits. Food Funct 3, 134140.CrossRefGoogle ScholarPubMed
19Milbury, PE, Chen, CY, Dolnikowski, GG, et al. (2006) Determination of flavonoids and phenolics and their distribution in almonds. J Agric Food Chem 54, 50275033.CrossRefGoogle ScholarPubMed
20Segura, R, Javierre, C, Lizarraga, MA, et al. (2006) Other relevant components of nuts: phytosterols, folate and minerals. Br J Nutr 96, Suppl. 2, S36S44. Erratum in (2008) Br J Nutr 99, 447–448.CrossRefGoogle ScholarPubMed
21Karppanen, H, Karppanen, P & Mervaala, E (2005) Why and how to implement sodium, potassium, calcium, and magnesium changes in food items and diets? J Hum Hypertens 19, S10S19.CrossRefGoogle ScholarPubMed
22Estruch, R, Ros, E, Salas-Salvadó, J, et al., for the PREDIMED Study Investigators (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368, 12791290. Erratum in (2014) N Engl J Med 370, 886.CrossRefGoogle ScholarPubMed
23Hu, FB, Stampfer, MJ, Manson, JE, et al. (1998) Frequent nut consumption and risk of coronary heart disease in women. Prospective cohort study. BMJ 317, 13411345.CrossRefGoogle ScholarPubMed
24Albert, CM, Gaziano, JM, Willett, WC, et al. (2002) Nut consumption and decreased risk of sudden cardiac death in the Physicians' Health Study. Arch Intern Med 162, 13821387.CrossRefGoogle ScholarPubMed
25Blomhoff, R, Carlsen, MH, Andersen, LF, et al. (2006) Health benefits of nuts: potential role of antioxidants. Br J Nutr 96, Suppl. 2, S52S60.CrossRefGoogle ScholarPubMed
26Kelly, JH & Sabaté, J (2006) Nuts and coronary heart disease: an epidemiological perspective. Br J Nutr 96, S61S67.CrossRefGoogle Scholar
27Guasch-Ferré, M, Bulló, M, Martínez-González, MA, et al., PREDIMED study group (2013) Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial. BMC Med 11, 164.CrossRefGoogle ScholarPubMed
28Bao, Y, Han, J, Hu, FB, et al. (2013) Association of nut consumption with total and cause-specific mortality. N Engl J Med 369, 20012011.CrossRefGoogle ScholarPubMed
29Li, TY, Brennan, AM, Wedick, NM, et al. (2009) Regular consumption of nuts is associated with a lower risk of cardiovascular disease in women with type 2 diabetes. J Nutr 139, 13331338.CrossRefGoogle ScholarPubMed
30Dilis, V, Katsoulis, M, Lagiou, P, et al. (2012) Mediterranean diet and CHD: the Greek European Prospective Investigation into Cancer and Nutrition cohort. Br J Nutr 108, 699709.CrossRefGoogle ScholarPubMed
31Yochum, LA, Folsom, AR & Kushi, LH (2000) Intake of antioxidant vitamins and risk of death from stroke in postmenopausal women. Am J Clin Nutr 72, 476483.CrossRefGoogle ScholarPubMed
32Djoussé, L, Gaziano, JM, Kase, CS, et al. (2010) Nut consumption and risk of stroke in US male physicians. Clin Nutr 29, 605609.CrossRefGoogle ScholarPubMed
33Bernstein, AM, Pan, A, Rexrode, KM, et al. (2012) Dietary protein sources and the risk of stroke in men and women. Stroke 43, 637644.CrossRefGoogle ScholarPubMed
34Jiang, R, Manson, JE, Stampfer, MJ, et al. (2002) Nut and peanut butter consumption and risk of type 2 diabetes in women. JAMA 288, 25542560.CrossRefGoogle ScholarPubMed
35Parker, ED, Harnack, LJ & Folsom, AR (2003) Nut consumption and risk of type 2 diabetes. JAMA 290, 3839; author reply 39–40.CrossRefGoogle ScholarPubMed
36Villegas, R, Gao, YT, Yang, G, et al. (2008) Legume and soy food intake and the incidence of type 2 diabetes in the Shanghai Women's Health Study. Am J Clin Nutr 87, 162167.CrossRefGoogle ScholarPubMed
37Kochar, J, Gaziano, JM & Djoussé, L (2010) Nut consumption and risk of type II diabetes in the Physicians' Health Study. Eur J Clin Nutr 64, 7579.CrossRefGoogle ScholarPubMed
38Pan, A, Sun, Q, Manson, JE, et al. (2013) Walnut consumption is associated with lower risk of type 2 diabetes in women. J Nutr 143, 512518.CrossRefGoogle ScholarPubMed
39Ibarrola-Jurado, N, Bulló, M, Guasch-Ferré, M, et al., PREDIMED Study Investigators (2013) Cross-sectional assessment of nut consumption and obesity, metabolic syndrome and other cardiometabolic risk factors: the PREDIMED study. PLOS ONE 8, e57367.CrossRefGoogle ScholarPubMed
40Fernández-Montero, A, Bes-Rastrollo, M, Beunza, JJ, et al. (2013) Nut consumption and incidence of metabolic syndrome after 6-year follow-up: the SUN (Seguimiento Universidad de Navarra Follow-up) cohort. Public Health Nutr 16, 20642072.CrossRefGoogle ScholarPubMed
41O'Neil, CE, Keast, DR, Nicklas, TA, et al. (2011) Nut consumption is associated with decreased health risk factors for cardiovascular disease and metabolic syndrome in U.S. adults: NHANES 1999–2004. J Am Coll Nutr 30, 502510.CrossRefGoogle ScholarPubMed
42Steffen, LM, Kroenke, CH, Yu, X, et al. (2005) Associations of plant food, dairy product, and meat intakes with 15-y incidence of elevated blood pressure in young black and white adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Clin Nutr 82, 11691177.CrossRefGoogle ScholarPubMed
43Djoussé, L, Rudich, T & Gaziano, JM (2009) Nut consumption and risk of hypertension in US male physicians. Clin Nutr 28, 1014.CrossRefGoogle ScholarPubMed
44Martínez-Lapiscina, EH, Pimenta, AM, Beunza, JJ, et al. (2010) Nut consumption and incidence of hypertension: the SUN prospective cohort. Nutr Metab Cardiovasc Dis 20, 359365.CrossRefGoogle ScholarPubMed
45Weng, LC, Steffen, LM, Szklo, M, et al. (2013) A diet pattern with more dairy and nuts, but less meat is related to lower risk of developing hypertension in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) study. Nutrients 5, 17191733.CrossRefGoogle ScholarPubMed
46Sabaté, J, Oda, K & Ros, E (2010) Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials. Arch Intern Med 170, 821827.CrossRefGoogle ScholarPubMed
47Banel, DK & Hu, FB (2009) Effects of walnut consumption on blood lipids and other cardiovascular risk factors: a meta-analysis and systematic review. Am J Clin Nutr 90, 5663.CrossRefGoogle ScholarPubMed
48Torabian, S, Haddad, E, Cordero-MacIntyre, Z, et al. (2010) Long-term walnut supplementation without dietary advice induces favorable serum lipid changes in free-living individuals. Eur J Clin Nutr 64, 274279.CrossRefGoogle ScholarPubMed
49Tapsell, LC, Batterham, MJ, Teuss, G, et al. (2009) Long-term effects of increased dietary polyunsaturated fat from walnuts on metabolic parameters in type II diabetes. Eur J Clin Nutr 63, 10081015.CrossRefGoogle ScholarPubMed
50Kendall, CW, Josse, AR, Esfahani, A, et al. (2010) Nuts, metabolic syndrome and diabetes. Br J Nutr 104, 465473.CrossRefGoogle ScholarPubMed
51Jenkins, DJ, Kendall, CW & Banach, MS (2011) Nuts as a replacement for carbohydrates in the diabetic diet. Diabetes Care 34, 17061711.CrossRefGoogle ScholarPubMed
52Li, SC, Liu, YH, Liu, JF, et al. (2011) Almond consumption improved glycemic control and lipid profiles in patients with type 2 diabetes mellitus. Metabolism 60, 474479.CrossRefGoogle ScholarPubMed
53Bes-Rastrollo, M, Sabaté, J, Gómez-Gracia, E, et al. (2007) Nut consumption and weight gain in a Mediterranean cohort: the SUN Study. Obesity (Silver Spring) 15, 107116.CrossRefGoogle Scholar
54Bes-Rastrollo, M, Wedick, NM, Martínez-González, MA, et al. (2009) Prospective study of nut consumption, long-term weight change, and obesity risk in women. Am J Clin Nutr 89, 19131919.CrossRefGoogle ScholarPubMed
55Mozaffarian, D, Hao, T, Rimm, EB, et al. (2011) Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 364, 23922404.CrossRefGoogle ScholarPubMed
56Casas-Agustench, P, Bulló, M, Ros, E, et al. (2011) Cross-sectional association of nut intake with adiposity in a Mediterranean population. Nutr Metab Cardiovasc Dis 21, 518525.CrossRefGoogle Scholar
57Martínez-González, MA, García-Arellano, A, Toledo, E, et al., PREDIMED Study Investigators (2012) A 14-item Mediterranean diet assessment tool and obesity indexes among high-risk subjects: the PREDIMED trial. PLOS ONE 7, e43134.CrossRefGoogle ScholarPubMed
58Flores-Mateo, G, Rojas-Rueda, D, Basora, J, et al. (2013) Nut intake and adiposity: meta-analysis of clinical trials. Am J Clin Nutr 97, 13461355.CrossRefGoogle ScholarPubMed
59Mattes, RD, Kris-Etherton, PM & Foster, GD (2008) Impact of peanuts and tree nuts on body weight and healthy weight loss in adults. J Nutr 138, 1741S1745S.CrossRefGoogle ScholarPubMed
60Ellis, PR, Kendall, CW, Ren, Y, et al. (2004) Role of cell walls in the bioaccessibility of lipids in almond seeds. Am J Clin Nutr 80, 604613.CrossRefGoogle ScholarPubMed
61Ros, E (2009) Nuts and novel biomarkers of cardiovascular disease. Am J Clin Nutr 89, 1649S1656S.CrossRefGoogle ScholarPubMed
62Casas-Agustench, P, López-Uriarte, P, Ros, E, et al. (2011) Nuts, hypertension and endothelial function. Nutr Metab Cardiovasc Dis 21, S21S33.CrossRefGoogle ScholarPubMed
63Ros, E, Núñez, I, Pérez-Heras, A, et al. (2004) A walnut diet improves endothelial function in hypercholesterolemic subjects. A randomized crossover trial. Circulation 109, 16091614.CrossRefGoogle ScholarPubMed
64Cortés, B, Núñez, I, Cofán, M, et al. (2006) Acute effects of high-fat meals enriched with walnuts or olive oil on postprandial endothelial function in healthy subjects and patients with hypercholesterolemia. J Am Coll Cardiol 48, 16661671.CrossRefGoogle ScholarPubMed
65Ma, Y, Njike, VY, Millet, J, et al. (2010) Effects of walnut consumption on endothelial function in type 2 diabetic subjects: a randomized controlled crossover trial. Diabetes Care 33, 227232.CrossRefGoogle ScholarPubMed
66West, SG, Krick, AL, Klein, LC, et al. (2010) Effects of diets high in walnuts and flax oil on hemodynamic responses to stress and vascular endothelial function. J Am Coll Nutr 29, 595603.CrossRefGoogle ScholarPubMed
67Zhao, G, Etherton, TD, Martin, KR, et al. (2004) Dietary α-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr 134, 29912997.CrossRefGoogle ScholarPubMed
68Zhao, G, Etherton, TD, Martin, KR, et al. (2007) Dietary α-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. Am J Clin Nutr 85, 385391.CrossRefGoogle ScholarPubMed
69West, SG, Gebauer, SK, Kay, CD, et al. (2012) Diets containing pistachios reduce systolic blood pressure and peripheral vascular responses to stress in adults with dyslipidemia. Hypertension 60, 5863.CrossRefGoogle ScholarPubMed
70López-Uriarte, P, Bulló, M, Casas-Agustench, P, et al. (2009) Nuts and oxidation: a systematic review. Nutr Rev 67, 497508.CrossRefGoogle ScholarPubMed
71Jenkins, DJ, Kendall, CW, Marchie, A, et al. (2008) Almonds reduce biomarkers of lipid peroxidation in older hyperlipidemic subjects. J Nutr 138, 908913.CrossRefGoogle ScholarPubMed
72Jenkins, DJ, Kebdall, CW, Marchie, A, et al. (2002) Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial. Circulation 106, 13271332.CrossRefGoogle ScholarPubMed
73Kay, CD, Gebauer, SK, West, SG, et al. (2010) Pistachios increase serum antioxidants and lower serum oxidized-LDL in hypercholesterolemic adults. J Nutr 140, 10931098.CrossRefGoogle ScholarPubMed
74Orem, A, Yucesan, FB, Orem, C, et al. (2013) Hazelnut-enriched diet improves cardiovascular risk biomarkers beyond a lipid-lowering effect in hypercholesterolemic subjects. J Clin Lipidol 7, 123131.CrossRefGoogle ScholarPubMed
75Berryman, CE, Grieger, JA, West, SG, et al. (2013) Acute consumption of walnuts and walnut components differentially affect postprandial lipemia, endothelial function, oxidative stress, and cholesterol efflux in humans with mild hypercholesterolemia. J Nutr 143, 788794.CrossRefGoogle ScholarPubMed
76Damasceno, NR, Sala-Vila, A, Cofán, M, et al. (2013) Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk. Atherosclerosis 230, 347353.CrossRefGoogle ScholarPubMed
77Estruch, R, Martínez-González, MA, Corella, D, et al., on behalf of the PREDIMED Study Investigators (2006) Effects of a Mediterranean-style diet on cardiovascular risk factors. A randomized trial. Ann Intern Med 145, 111.CrossRefGoogle ScholarPubMed
78Fitó, M, Guxens, M, Corella, D, et al., on behalf of the PREDIMED Study Investigators (2007) Effect of a traditional Mediterranean diet on lipoprotein oxidation. A randomized controlled trial. Arch Intern Med 167, 11951203.CrossRefGoogle ScholarPubMed
79Doménech, M, Roman, P, Lapetra, J, et al. (2014) Mediterranean diet reduces 24-hour ambulatory blood pressure, blood glucose, and lipids: one-year randomized, clinical trial. Hypertension 64, 6976.CrossRefGoogle ScholarPubMed
80Mena, MP, Sacanella, E, Vázquez-Agell, M, et al. (2009) Inhibition of circulating immune cell activation: a molecular antiinflammatory effect of the Mediterranean diet. Am J Clin Nutr 89, 248256.CrossRefGoogle ScholarPubMed
81Sala-Vila, A, Romero-Mamani, ES, Gilabert, R, et al. (2014) Changes in ultrasound-assessed carotid intima-media thickness and plaque with a Mediterranean diet: a substudy of the PREDIMED trial. Arterioscler Thromb Vasc Biol 34, 439445.CrossRefGoogle ScholarPubMed
82Salas-Salvadó, J, Fernández-Ballart, J, Ros, E, et al., on behalf of the PREDIMED Study Investigators (2008) Effect of the Mediterranean diet supplemented with nuts on metabolic syndrome status. One-year results of the PREDIMED randomized trial. Arch Intern Med 168, 24492458.CrossRefGoogle ScholarPubMed
83Salas-Salvadó, J, Bulló, M, Babio, N, et al., for the PREDIMED Study investigators (2011) Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-REUS dietary intervention trial. Diabetes Care 34, 1419.CrossRefGoogle Scholar
84Salas-Salvadó, J, Bulló, M, Estruch, R, et al. (2014) Prevention of diabetes with Mediterranean diets. A subgroup analysis of a randomized trial. Ann Intern Med 160, 110.CrossRefGoogle ScholarPubMed
85Ruiz-Canela, M, Estruch, R, Corella, D, et al. (2014) Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial. JAMA 311, 415417.CrossRefGoogle ScholarPubMed
Figure 0

Table 1 Average composition of nuts in macro- and micronutrients and selected phytochemicals (per 100 g)*

Figure 1

Fig. 1 Incidence of fatal CHD by frequency of nut intake. Shown are the results of six large prospective studies where nut consumption was the exposure of interest and the outcome was death from CHD. , Adventist Health Study, 1992; , Nurses' Health Study, 1998; , Physicians' Health Study, 2002; , Iowa Women's Health Study, 2006; , PREvención con DIeta MEDiterránea, 2013; , Nurses' Health Study and Health Professionals Follow-up Study, 2013. A colour version of this figure can be found online at

Figure 2

Fig. 2 Incidence of CVD by intervention group in the PREvención con DIeta MEDiterránea study. Med Diet with extra-virgin olive oil (EVOO): hazard ratios (HR) 0·70 (95 % CI 0·53, 0·91), P= 0·009; Med Diet with nuts: HR 0·70 (95 % CI 0·53, 0·94), P= 0·016. Med Diet, Mediterranean diet. Estruch et al.(22) copyright© (2013) Massachusetts Medical Society. Reprinted with permission. A colour version of this figure can be found online at

Figure 3

Table 2 Effects of nut consumption on CVD and risk factors. Summary of scientific evidence

You have Access
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the or variations. ‘’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Nuts and CVD
Available formats

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Nuts and CVD
Available formats

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Nuts and CVD
Available formats

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *